Health News Report Reprinted 2008-01-29

New Report Predicts that Novartis' Diovan, Glivec/Gleevec and Zelmac/
Zelnorm will Continue to Show Healthy Sales Growth

Saturday, August 11, 2007

Aug. 3, 2007 (M2 Communications Ltd. delivered by Newstex) --

Research and Markets (http://www.researchandmarkets.com/reports/
c64757) has announced the addition of Novartis: Performance, Products,
Pipeline and Potential to their offering

Pharmaceutical company intelligence reports provide a full review of
the company's activities together with five-year sales forecasts for
its key products. The company's financial performance is covered in-
depth, from its latest results to a complete analysis of
itscccccccclatest full fiscal year and an outlook for the future. A
section on company strategy covers mergers, acquisitions and
divestitures, key agreements, products and R&D. An overview of key
products and R&D is followed by a comprehensive review of the
company's product portfolio and research and development pipeline by
therapeutic area. In addition, supplementary appendices provide more
in-depth information on financials, agreements and corporate events.